Efficiency of dendritic cell vaccination against B16 melanoma depends on the immunization route

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Edele, Fanny ^a   Dudda, Jan C ^a,b   Bachtanian, Eva ^a   Jakob, Thilo ^a   Pircher, Hanspeter ^a   Martin, Stefan F ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLYCOPROTEIN; GLYCOPROTEIN PEPTIDE 33-41, LYMPHOCYTIC CHORIOMENINGITIS VIRUS; HOMING RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE FRAGMENT; VIRUS ANTIGEN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANIMAL; DENDRITIC CELL; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; PATHOLOGY; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, VIRAL; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLYCOPROTEINS; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, LYMPHOCYTE HOMING; T-LYMPHOCYTES; TUMOR BURDEN; VIRAL PROTEINS;

EID: 84905974355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105266     Document Type: Article

References (44)

1. Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12: 265-277.
2. Kalinski P, Muthuswamy R, Urban J (2013) Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 12: 285-295.
3. Frankenberger B, Schendel DJ (2012) Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol 91: 53-58.
4. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 105: R9-R14. (Pubitemid 30164122)
5. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, et al. (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9: 5091-5100. (Pubitemid 37413557)
6. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52-58. (Pubitemid 26028073)
7. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99: 1517-1526. (Pubitemid 34533020)
8. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166: 4254-4259. (Pubitemid 32224961)
9. Fong L, Hou Y, Rivas A, Benike C, Yuen A, et al. (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98: 8809-8814. (Pubitemid 32678109)
10. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332. (Pubitemid 28144092)
11. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190: 1669-1678. (Pubitemid 30002348)
12. Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, et al. (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104: 173-180.
13. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915. (Pubitemid 39273730)
14. Sims RB (2012) Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30: 4394-4397.
15. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, et al. (2003) Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198: 1023-1034. (Pubitemid 37248618)
16. Dudda JC, Simon JC, Martin S (2004) Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 172: 857-863. (Pubitemid 38113742)
17. Ohl L, Mohaupt M, Czeloth N, Hintzen G, Kiafard Z, et al. (2004) CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21: 279-288. (Pubitemid 39094056)
18. Yoneyama H, Matsuno K, Matsushimaa K (2005) Migration of dendritic cells. Int J Hematol 81: 204-207. (Pubitemid 41364485)
19. Bousso P, Robey E (2003) Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 4: 579-585. (Pubitemid 36701342)
20. Mullins DW, Engelhard VH (2006) Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J Immunol 176: 4535-4542.
21. Dudda JC, Lembo A, Bachtanian E, Huehn J, Siewert C, et al. (2005) Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol 35: 1056-1065. (Pubitemid 40542212)
22. Edele F, Molenaar R, Gutle D, Dudda JC, Jakob T, et al. (2008) Cutting edge: instructive role of peripheral tissue cells in the imprinting of T cell homing receptor patterns. J Immunol 181: 3745-3749.
23. Hammerschmidt SI, Ahrendt M, Bode U, Wahl B, Kremmer E, et al. (2008) Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 205: 2483-2490.
24. Molenaar R, Greuter M, van der Marel AP, Roozendaal R, Martin SF, et al. (2009) Lymph node stromal cells support dendritic cell-induced gut-homing of T cells. J Immunol 183: 6395-6402.
25. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, et al. (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22: 175-184.
26. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM (1989) Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342: 559-561. (Pubitemid 20005822)
27. Zimmerman C, Brduscha-Riem K, Blaser C, Zinkernagel RM, Pircher H (1996) Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J Exp Med 183: 1367-1375. (Pubitemid 26134280)
28. Kyburz D, Aichele P, Speiser DE, Hengartner H, Zinkernagel RM, et al. (1993) T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur J Immunol 23: 1956-1962. (Pubitemid 23236793)
29. Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, et al. (1998) Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol 161: 2187-2194. (Pubitemid 28397028)
30. Butz EA, Bevan MJ (1998) Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 8: 167-175. (Pubitemid 28123744)
31. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, et al. (1998) Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8: 177-187. (Pubitemid 28123745)
32. Murali-Krishna K, Altman JD, Suresh M, Sourdive D, Zajac A, et al. (1998) In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection. Adv Exp Med Biol 452: 123-142. (Pubitemid 28478091)
33. Grover A, Kim GJ, Lizee G, Tschoi M, Wang G, et al. (2006) Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12: 5801-5808. (Pubitemid 44629612)
34. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198: 615-621.
35. Dudda JC, Martin SF (2004) Tissue targeting of T cells by DCs and microenvironments. Trends Immunol 25: 417-421. (Pubitemid 38951082)
36. Sheasley-O'Neill SL, Brinkman CC, Ferguson AR, Dispenza MC, Engelhard VH (2007) Dendritic cell immunization route determines integrin expression and lymphoid and nonlymphoid tissue distribution of CD8 T cells. J Immunol 178: 1512-1522. (Pubitemid 46154622)
37. Brinkman CC, Sheasley-O'Neill SL, Ferguson AR, Engelhard VH (2008) Activated CD8 T cells redistribute to antigen-free lymph nodes and exhibit effector and memory characteristics. J Immunol 181: 1814-1824.
38. Obar JJ, Khanna KM, Lefrancois L (2008) Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
39. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, et al. (2004) Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol 172: 4875-4882. (Pubitemid 38456411)
40. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, et al. (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183: 87-97. (Pubitemid 26028748)
41. Moutsopoulos NM, Wen J, Wahl SM (2008) TGF-beta and tumors-an ill-fated alliance. Curr Opin Immunol 20: 234-240.
42. Morse MA, Hall JR, Plate JM (2009) Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther 9: 331-339.
43. Xu G, Zhang J (2008) Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival. J Cancer Res Clin Oncol 134: 1043-1049.
44. Abastado JP (2012) The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 72: 2159-2161.